Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue: +50.1%
EPS: +147.3%
Free cash flow: +53.5%
Total debt: +0.45%

Quarter to September 2026, against a year earlier

397.66 2.44 −0.61%

Follow MDGL

Alert me

Market cap: $9.3B
P/E: 0.0×
Fwd P/E: −68.8×
Dividend yield: —
F-score: n/a
Altman Z: 10.48
Beneish M: 0.50
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 3, 2026 · accepted 9:10 AM ET · Document on sec.gov · Filing index

Red flags

Receivables outpacing revenue Nov 3, 2026
Receivables grew 100.7% while revenue grew 50.1% year over year

10-Q filed Nov 3, 2026 · The filing · sec.gov
Inventory outpacing revenue Nov 3, 2026
Inventory grew 76.9% while revenue grew 50.1% year over year

10-Q filed Nov 3, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 4, 2025: 35 added · 19 removed · 43 modified; 6 with only figures updated

Madrigal Pharmaceuticals, Inc. 10-Q filed Nov 3, 2026

Red flags

What changed

Stockrow Weekly